

ARIC Manuscript Proposal #2455

PC Reviewed: 10/14/14
SC Reviewed: _____

Status: A
Status: _____

Priority: 2
Priority: _____

1.a. Full Title: Peripheral Artery Disease and Quality of Life in the Community: The Atherosclerosis Risk in Communities Study

b. Abbreviated Title (Length 26 characters): PAD and QOL

2. Writing Group:

Writing group members:

Aozhou Wu, BMed, BS; Josef Coresh, MD, PhD, Elizabeth Selvin, PhD, MPH, Hirofumi Tanaka, PhD, Gerardo Heiss, MD, PhD, Alan Hirsch, MD, Bernard Jaar, MD; Kunihiro Matsushita, MD, PhD; others welcome.

I, the first author, confirm that all the coauthors have given their approval for this manuscript proposal. AW [please confirm with your initials electronically or in writing]

First author: Aozhou Wu, B Med, BS
Address: Department of Epidemiology
Johns Hopkins Bloomberg School of Public Health
650 Wolfe Street, W6017
Phone: (410)736-2558
E-mail: wuaozhou@gmail.com

ARIC author to be contacted if there are questions about the manuscript and the first author does not respond or cannot be located (this must be an ARIC investigator).

Name: Kunihiro Matsushita, MD, PhD
Address: Department of Epidemiology
Johns Hopkins Bloomberg School of Public Health
Welch Center for Prevention, Epidemiology, and Clinical Research
650 Wolfe Street, W6017
Phone: (443) 287-8766 Fax: (443) 683-8358
E-mail: kmatsush@jhsph.edu

3. Timeline:

Data to be used in this proposal are already available. Analyses and manuscript preparation will be performed over the next 6 months.

4. Rationale:

Peripheral arterial disease (PAD), commonly identified by an ankle brachial index (ABI) less than 0.9, is common, especially in older adults. In the US, PAD affects over 7 millions individuals (1), including 20% of people aged over 70 years (2, 3). PAD patients have 4-fold higher mortality risk compared with those without PAD (4-6). This is mainly due to higher risk of cardiovascular diseases (CVD), reflecting the property of PAD as a manifestation of systemic atherosclerosis (7).

PAD can also have a substantial impact on patients' quality of life (QOL). As the disease progress, patients may develop claudication and critical limb ischemia (CLI, a condition including limb rest pain, unhealing ulcers or gangrene, and with a rate of amputation reaching up to 25% within one year after diagnosis (8)), resulting in substantial loss of physical functioning, poor QOL (9-14). However most evidence come from small clinical studies (N<~1,000), typically in symptomatic PAD patients recruited from vascular clinics. Prospective investigations of the long-term impact of PAD on QOL and deterioration over time are lacking.

The aim of this study will be to comprehensively investigate the association of PAD-related measures (ABI, leg symptoms by questionnaires, clinical history of PAD during follow-up time, severe disease condition-CLI) with QOL parameters (self-reported health status, physical function/activity, nursing demand, and social status) in a bi-ethnic community-based cohort, the ARIC Study, at and over different stages of life (middle-age and older age) during 25 years of follow-up.

5. Study Aim and Main Hypothesis:

PAD measures are independently associated with poor status of QOL

6. Design and analysis

Study design:

We will use cross-sectional, prospective and case-control designs according to data availability (as summarized in appendix Table on the last page) and study angle summarized below:

- Cross-sectional evaluation of the association between PAD-related measures (ABI, leg symptoms, and history of clinical PAD) and QOL parameters at ARIC visits with key variables of interest (appendix Table 1) (it is likely that visits 1 and 5 with ABI in literally all participants will be primary visits of interest and visits 3 and 4 with ABI in a subsample will be used for secondary analysis).
- Prospective investigation of the contribution of PAD-related measures to subsequent changes in QOL parameters (earlier visits such as visit 1 with long follow-up will be used for primary analysis).
- Given that these two approaches may not capture severe PAD cases like those with critical limb ischemia with 1-year mortality of ~20% (15). To specifically analyze the association of critical limb ischemia with QOL, we will also implement case-control analysis as detailed below.

Study population:

Inclusion criteria:

White and African-American participants, with key data on PAD-related measures and QOL parameters (appendix Table 1) at visits of interest.

Exclusion criteria:

Non-white/non-black participants or those with missing information on key PAD-related measures and QOL parameters at visits of interest.

Exposure

- *Ankle brachial index (ABI):* ABI, the ratio of ankle to brachial blood pressure was based on ankle and brachial systolic blood pressures measured with DINAMAP automated oscillometric device at visits 1, 3, and 4 and with OMRON VP-2000 at visit 5.
- *Leg symptom:* Self-reported leg pain at rest or during walk.
- *History of Clinical PAD:* Clinical diagnosis of PAD prior to visits of interest based on self-report and ICD-9 codes: Peripheral vascular disease (443.9); Atherosclerosis of native arteries of the extremities, unspecified (440.20); Intermittent claudication (440.21); Atherosclerosis, extremities, w/ rest pain (440.22); Atherosclerosis of other specified arteries (440.8); Other specified peripheral vascular diseases (I73.8); Peripheral vascular disease, unspecified (I73.9); Amputation (84.1x), Amputation, not otherwise specified (84.91); Revascularization (38.08, 38.18, 38.38, 38.48, 39.25, 39.29, 39.49, 39.50, 39.56, 39.57, 39.58, 39.90); Atherosclerosis of bypass graft of the extremities (440.3); Lower extremity ulcer (707.1x); Atherosclerosis, extremities, w/ ulceration (440.23); Gangrene (785.4/440.24); Other atherosclerosis of native arteries of the extremities (440.29).

Covariates

Demographics: age, gender, race, socioeconomic status, and study center

Physical information: body mass index (BMI), blood pressure

Comorbidities: Hypertension, diabetes, dyslipidemia, coronary heart disease (CHD), heart failure (HF), stroke, and chronic kidney disease (CKD)

Outcome: QOL parameters (appendix Table 1 in the last page for more details)

1. Self-reported health status
2. Physical activity assessment (self-reported ability to walk or 4m-walk test without help, self-reported ability to climb stairs without help, and to do chores work around the house)
3. Social status (self-reported work performance, social activity, employee status, and marital status)
4. Mental status (CES depression score, general mental status in life, and medication use for depression)
5. Nursing demand (Needs on someone's help for personal care or stay in nursing house).

Statistical Analysis Plan:

We will first cross-sectionally assess the associations of PAD-related parameters (ABI, leg symptoms, and history of clinical PAD) with each component of QOL at relevant visits. The primary analysis will be conducted with data from visits 1 and 5, and sensitivity analysis will be performed with data from visits 3 and 4. As most of these

QOL parameters are coded as binary variables, logistic regression will be mainly used with the adjustment for covariates listed above. Multinomial logistic regression models will be also implemented in some QOL parameters with multiple categories, as appropriate. We will repeat the analysis in several demographic (age, gender and race) and clinical (hypertension, diabetes, dyslipidemia, CHD, and CKD) subgroups.

Subsequently, we will explore the prospective association of PAD-related measures with changes in QOL parameters during follow-up. To maximize follow-up, we will primarily use visit 1 as baseline. The key QOL outcome variables with frequent repeated assessments for this analysis will be self-reported health status, ability to walk without help, marital status, employment status, health problem interfering work or retirement due to health problem, CES depression score, general mental status in life, medication use for depression. Cox proportional hazards and logistic regression models will be used to evaluate the association of PAD-related measures with subsequent QOL, adjusting for covariates listed above. Similar to *Aim 1a*, we will repeat the analysis in various demographic and clinical subgroups.

To specifically evaluate the impact of severe PAD cases (i.e., critical limb ischemia) that may not be necessarily captured in the above cross-sectional and prospective analyses, we will perform age-, gender-, and race-matched case-control investigation, with match ratio of 1: 3, using density-sampling strategy for severe PAD cases and controls. Severe PAD cases will be identified according to hospitalizations with the following ICD-9 codes: Atherosclerosis, extremities, w/ rest pain (440.22); Amputation (84.1x), Amputation, not otherwise specified (84.91); Lower extremity ulcer (707.1x); Atherosclerosis, extremities, w/ ulceration (440.23); Gangrene (785.4/440.24). Controls will be selected using age-, gender-, and race-matched density-sampling strategy. We will test whether QOL parameters summarized above are different between participants with and without severe PAD, using conditional logistic regression models. We will also evaluate whether important comorbidities related to PAD such as diabetes, CKD, and CHD contribute to further decrease in QOL.

Limitations:

ABI was only measured in a randomly selected single leg at visit 1. Only a few QOL parameters were assessed uniformly over the follow-up, and thus we will perform several analyses using different time frames. Thus, we may need to summarize our results in a few manuscripts.

7.a. Will the data be used for non-CVD analysis in this manuscript? Yes
 No

b. If Yes, is the author aware that the file ICTDER03 must be used to exclude persons with a value RES_OTH = “CVD Research” for non-DNA analysis, and for DNA analysis RES_DNA = “CVD Research” would be used?
Yes No

(This file ICTDER03 has been distributed to ARIC PIs, and contains the responses to consent updates related to stored sample use for research.)

8.a. Will the DNA data be used in this manuscript? ___ Yes __X__ No

8.b. If yes, is the author aware that either DNA data distributed by the Coordinating Center must be used, or the file ICTDER03 must be used to exclude those with value RES_DNA = “No use/storage DNA”?
 ___ Yes ___ No

8.c. If yes, is the author aware that the participants with RES_DNA = ‘not for profit’ restriction must be excluded if the data are used by a for profit group?
 ___ Yes ___ No

9. The lead author of this manuscript proposal has reviewed the list of existing ARIC Study manuscript proposals and has found no overlap between this proposal and previously approved manuscript proposals either published or still in active status. ARIC Investigators have access to the publications lists under the Study Members Area of the web site at: <http://www.csc.unc.edu/ARIC/search.php>

__X__ Yes _____ No

10. What are the most related manuscript proposals in ARIC (authors are encouraged to contact lead authors of these proposals for comments on the new proposal or collaboration)?

To our knowledge, there are no ARIC proposals specifically focusing on PAD and QOL. As physical activity as a domain of QOL, MP 2312 “Ankle-brachial index and physical function and activity in older individuals” is most relevant. However, key authors of that manuscript contribute to the current proposal and appropriate coordination will be made.

11. a. Is this manuscript proposal associated with any ARIC ancillary studies or use any ancillary study data? ___ Yes __X__ No

11.b. If yes, is the proposal

___ A. primarily the result of an ancillary study (list number* _____)

___ B. primarily based on ARIC data with ancillary data playing a minor role (usually control variables; list number(s)* _____)

*ancillary studies are listed by number at <http://www.csc.unc.edu/aric/forms/>

12. Manuscript preparation is expected to be completed in one to three years. If a manuscript is not submitted for ARIC review at the end of the 3-years from the date of the approval, the manuscript proposal will expire.

References

1. Pande RL, Perlstein TS, Beckman JA, Creager MA. Secondary prevention and mortality in peripheral artery disease: National Health and Nutrition Examination Study, 1999 to 2004. *Circulation*. 2011;124(1):17-23.
2. Selvin E, Erlinger TP. Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999-2000. *Circulation*. 2004;110(6):738-43.
3. Ostchega Y, Paulose-Ram R, Dillon CF, Gu Q, Hughes JP. Prevalence of peripheral arterial disease and risk factors in persons aged 60 and older: data from the National Health and Nutrition Examination Survey 1999-2004. *J Am Geriatr Soc*. 2007;55(4):583-9.
4. Murabito JM, Evans JC, Larson MG, Nieto K, Levy D, Wilson PW. The ankle-brachial index in the elderly and risk of stroke, coronary disease, and death: the Framingham Study. *Arch Intern Med*. 2003;163(16):1939-42.
5. Minar E. Critical limb ischaemia. *Hämostaseologie*. 2009;29(1):102-9.
6. Heald CL, Fowkes FG, Murray GD, Price JF. Risk of mortality and cardiovascular disease associated with the ankle-brachial index: Systematic review. *Atherosclerosis*. 2006;189(1):61-9.
7. Roger VL, Go AS, Lloyd-Jones DM, Benjamin EJ, Berry JD, Borden WB, et al. Heart disease and stroke statistics--2012 update: a report from the American Heart Association. *Circulation*. 2012;125(1):e2-e220.
8. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FGR. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). *Journal of Vascular Surgery*;45(1):S5-S67.
9. McDermott MM, Liu K, Greenland P, Guralnik JM, Criqui MH, Chan C, et al. Functional decline in peripheral arterial disease: associations with the ankle brachial index and leg symptoms. *Jama*. 2004;292(4):453-61.
10. Dumville JC, Lee AJ, Smith FB, Fowkes FG. The health-related quality of life of people with peripheral arterial disease in the community: the Edinburgh Artery Study. *Br J Gen Pract*. 2004;54(508):826-31.
11. McDermott MM, Greenland P, Liu K, Guralnik JM, Criqui MH, Dolan NC, et al. Leg symptoms in peripheral arterial disease: associated clinical characteristics and functional impairment. *Jama*. 2001;286(13):1599-606.
12. Chetter IC, Spark JI, Dolan P, Scott DJ, Kester RC. Quality of life analysis in patients with lower limb ischaemia: suggestions for European standardisation. *Eur J Vasc Endovasc Surg*. 1997;13(6):597-604.
13. Amer MS, Alsadany MA, Tolba MF, Omar OH. Quality of life in elderly diabetic patients with peripheral arterial disease. *Geriatrics & Gerontology International*. 2013;13(2):443-50.
14. Breek JC, Hamming JF, De Vries J, Aquarius AEAM, van Berge Henegouwen DP. Quality of Life in Patients with Intermittent Claudication Using The World Health Organisation (WHO) Questionnaire. *European Journal of Vascular and Endovascular Surgery*. 2001;21(2):118-22.
15. Varu VN, Hogg ME, Kibbe MR. Critical limb ischemia. *J Vasc Surg*. 2010;51(1):230-41.

